Medivation Inc (NASDAQ:MDVN), the most attractive acquisition target for large drug makers seeking high growth assets specifically in the area of oncology, faces a crucial decision at this point as Sanofi SA (ADR) (NYSE:SNY) advances with its takeover attempts. The cancer drug maker remains committed to its previous decision of rejecting Sanofi’s bid as it considers it too low in value, and it has urged its shareholders to vote against the deal.
